AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $5.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$5.4M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 5 cutMore cutting
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $366.55
- 52-wk high
- $385.75
- High
- $378.47
- 52-wk low
- $223.52
- Low
- $366.55
- Prev close
- $370.44
- Mkt cap
- $26.51B
- P/E
- 48.2x
- Volume
- 567.6K
- Fwd P/E
- 37.0x
- Beta
- 1.14
- Div yield
- 0.23%
- P/S
- 8.0x
- P/B
- 6.7x
- Profit margin
- +17.0%
- Op margin
- +22.5%
- ROE
- +19.1%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about WST filings
Are insiders buying or selling West Pharmaceutical Services Inc (WST) stock?
Net selling: insiders sold $5.4M and bought $0 of WST stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $2.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Favorite, Annette F (Sr. VP & Chief HR Officer), who sold $5.4M. The latest filing was on Sep 15, 2026.
Which members of Congress have traded WST recently?
None. No member of Congress disclosed a WST trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this WST smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- P7
Point72
$61.8M
added
Sells/Trims (2)
- VG
Viking Global
$81.2M
sold
- MI
Millennium
$64.2M
trimmed
What insiders are doing
How top traders are positioned
No tracked top-trader positions in WST right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 13.9% above what analysts expected.
Earnings per share
$2.08 expected
Revenue
No comparable estimate
Q3 2026 guidance
$820.0M to $835.0M
No comparable estimate
Reports Oct 22, 2026, in 21 days
Estimates as of Sep 30, 2026
EPS expected
$2.16 to $2.23
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $804.3M | $805.0M | $844.9M | $872.3M |
| Cost of what it sold | $510.8M | $501.1M | $548.5M | $543.1M |
| Gross profit | $293.5M | $303.9M | $296.4M | $329.2M |
| What it spent | ||||
| Research and development | $17.1M | $21.8M | $15.8M | $19.7M |
| Sales and admin | $102.7M | $106.5M | $99.5M | $117.6M |
| Other operating costs | — | $18.5M | $4.0M | $12.8M |
| Total operating expenses | $119.8M | $146.8M | $119.3M | $150.1M |
| What was left | ||||
| Operating profit | $173.7M | $156.6M | $177.1M | $179.1M |
| Interest on debt | $100.0K | $5.3M | $1.9M | $2.6M |
| Profit before tax | $174.0M | $165.4M | $180.1M | $180.1M |
| Tax | $34.0M | $33.3M | $44.7M | $32.2M |
| Net profit | $140.0M | $132.1M | $138.8M | $154.0M |
| EBITDA | $217.1M | $209.5M | $218.5M | $179.1M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Top West Pharmaceutical Services (WST) Competitors 2026
NeutralSep 25West Pharmaceutical Services stock gains after target rises
BullishSep 24West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says
BullishSep 23West Pharmaceutical stock rises 2.71 percent after analyst upgrade
BullishSep 23West Pharmaceutical Services stock holds near its yearly range
Leans bearishSep 22WST: GLP 1 Is Only Part Of The Story, Margins Look More Durable
BullishSep 22Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $365
BullishSep 22West Pharmaceutical Services (WST) Could Be 10% Undervalued On GLP 1 And Annex 1 Demand
Leans bullishSep 20
Macro
32 macro signals shaping WST right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results